8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

July 27, 2009
Date of Report (Date of earliest event reported)

WATSON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada	001-13305	95-3872914
(State of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

311 Bonnie Circle
Corona, California, 92880
(Address of principal executive offices) (Zip Code)

(951) 493-5300
(Registrant’s telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On July 27, 2009, Watson Pharmaceuticals, Inc. (the “Company”) announced that Mark W. Durand, Senior Vice President and Chief Financial Officer of the Company, has taken a leave of absence from the Company, effective immediately.

(c) On July 27, 2009, R. Todd Joyce was appointed to serve as the acting Principal Financial Officer of the Company, effective immediately. Mr. Joyce, age 51, has served as the Company’s Vice President, Corporate Controller Treasurer since 2001 and served as the Company’s interim Principal Financial Officer from October 2006 until November 2007. Mr. Joyce will continue to be compensated pursuant to his existing employment agreement with the Company.

Item 9.01 Financial Statements and Exhibits

     d. Exhibits:

 Ex. 99.1  Press release issued by Watson Pharmaceuticals, Inc. on July 27, 2009

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 28, 2009	By:	/s/ David A. Buchen
		David A. Buchen
		Senior Vice President, General Counsel and Secretary

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release issued by Watson Pharmaceuticals, Inc. on July 27, 2009

EX-99.1

Exhibit 99.1

PRESS RELEASE

CONTACTS:	Patty Eisenhaur
	Watson Pharmaceuticals, Inc.
	951-493-5611
	patty.eisenhaur@watson.c

Watson CFO Mark W. Durand to Take Leave of Absence

MORRISTOWN, N.J., July 27 /PRNewswire-FirstCall/ — Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced that effective today Mark W. Durand, Senior Vice President and Chief Financial Officer, has taken a leave of absence from the Company for health reasons. Paul Bisaro, President and Chief Executive Officer of Watson, announced that R. Todd Joyce, Vice President, Corporate Controller and Treasurer, will serve as Acting Principal Financial Officer, effective immediately.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., (NYSE: WPI) is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).
For press releases and other company information, visit the Watson website at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson’s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson’s current expectations depending upon a number of factors affecting Watson’s business. These factors include, among others, the risks and uncertainties detailed in Watson’s periodic public filings with the Securities and Exchange Commission, including but not limited to Watson’s Annual Report on Form 10-K for the year ended December 31, 2008.
        .

###